ERBB2 and cancer: After surgery and adjuvant therapy, treatment with autologous dendritic cells pulsed with a HER2 intracellular domain peptide significantly reduced the risk of cancer recurrence in all seven patients in a small clinical setting (NCT00005956) with high HER2 expressing breast cancer (stage II-IV) and six patients showed anti-HER2 antibody [213].